AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00641511
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once per day placebo capsules
Trial: NCT00752401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
Trial: NCT00710125
Drug: GPX-150 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
Trial: NCT01547559
Drug: part1:EAC-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
Trial: NCT01547559
Drug: part1:EA-EMC-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
Trial: NCT01547559
Drug: part2:GGA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
Trial: NCT02737891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01342237
Drug: HDCT 1(TTC), HDCT2(MEC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~2. MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)
Trial: NCT04369261
Drug: Synovian®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synovian® Inj.
Trial: NCT02675556
Drug: Allo-hMSCs
RxNorm normalized name: allo-2-hydroxycitric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells
Trial: NCT02675556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
Trial: NCT03441373
Drug: XC8 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily during 5 days.
Trial: NCT03441373
Drug: XC8 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily during 5 days.
Trial: NCT03441373
Drug: XC8 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily during 5 days.
Trial: NCT03441373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily during 5 days.
Trial: NCT02424799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
Trial: NCT04355585
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
Trial: NCT01845194
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment period 2:~5 mg Codeine once
Trial: NCT01845194
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment period 2:~5 mg Pravastatin once
Trial: NCT01845194
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment period 1:~50 mg Caffeine 3x
Trial: NCT02987114
Drug: PLT101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
Trial: NCT03545971
Drug: IBI310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI310 is anti CTLA-4 antibody
Trial: NCT00079365
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00681356
Drug: 4975, 15 and 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct instillation into the surgical site
Trial: NCT00681356
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct instillation into the surgical site
Trial: NCT01481194
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 IV on day 1 of a 21-day cycle
Trial: NCT01481194
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 IV on day 1 of a 21-day cycle
Trial: NCT00644085
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of placebo
Trial: NCT02080819
Drug: levodopa/carbidopa 400/100 BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance.
Trial: NCT01788215
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg/day in divided doses of 100mg twice daily
Trial: NCT01912469
Drug: Traumeel
RxNorm normalized name: Traumeel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Trial: NCT01912469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Trial: NCT04354597
Drug: HCQ & AZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.
Trial: NCT01630538
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
Trial: NCT02636361
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT00612105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily
Trial: NCT01443624
Drug: critical care patients venofer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
Trial: NCT01651962
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01651962
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03730142
Drug: WXFL10030390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WXFL10030390 is a tablet in the form of 0.1mg and 0.5mg, oral, once a day.
Trial: NCT01411735
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg titrated up to 10mg twice daily.
Trial: NCT02428478
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg administered 2 hours before normal sleep time
Trial: NCT02428478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching desipramine administered 2 hours before normal sleep time
Trial: NCT00029146
Drug: best medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: best current practice medical therapy
Trial: NCT01775397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT01577082
Drug: CHF1535 200/6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
Trial: NCT01577082
Drug: BDP 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone Dipropionate 800µg daily during 12 weeks
Trial: NCT02377661
Drug: Olmesartan medoxomil, amlodipine, hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of \< 140/90 mmHg is not reached at the respective follow-up
Trial: NCT00004930
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02692391
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.
Trial: NCT02692391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
Trial: NCT00539188
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
Trial: NCT05427617
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician chosen treatment
Trial: NCT05427617
Drug: Case group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Druggable ctDNA alterations-guided therapy
Trial: NCT04636983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT00272025
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03183739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally.
Trial: NCT00710086
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
Trial: NCT02916537
Drug: CTT1057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).
Trial: NCT00637702
Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose and multiple dose, escalating
Trial: NCT03790033
Drug: Ucha-Shinki-Hwan
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g Achyranthes Root 1.0g Cornus Fruit 1.0g Dioscorea Rhizome 1.0g Psyllium Husk 1.0g Alisma Rhizome 1.0g Hoelen 1.0g Moutan Root Bark 1.0g Cinnamon Bark 0.3g Pulvis Aconiti Tuberis Purificatum 0.3g
Trial: NCT03790033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo granule
Trial: NCT03272568
Drug: Recombinant FIX Fc fusion product Alprolix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
Trial: NCT03485300
Drug: Drug or food interactions
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
Trial: NCT01008423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
Trial: NCT01064375
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
Trial: NCT00147836
Drug: Human Insulin NPH (Novolin-N, Novo Nordisk)
RxNorm normalized name: insulin isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00147836
Drug: Diamicron and Glucophage
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03800420
Drug: BBT-401-1S first and then Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total 16 week treatment period: The subject takes BBT-401-1S, QD for the first 12 weeks, then placebo for the last 4 weeks.
Trial: NCT03800420
Drug: Placebo first and then BBT-401-1S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total 16 week treatment period: The subject takes the placebo, QD for the first 8 weeks, then BBT-401-1S for the last 8 weeks.
Trial: NCT03078829
Drug: Treatment with a GnRh agonists
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be treated with GnRH agonists
Trial: NCT00651079
Drug: GSK1247303
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00401687
Drug: Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention for this study was that all patients received a slow bolus injection of diluted DEFINITY during the contrast-enhanced imaging study.
Trial: NCT00605956
Drug: NatrOVA Creme Rinse - 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NatrOVA Creme Rinse - 1% spinosad
Trial: NCT00605956
Drug: Blank Patch
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank Patch
Trial: NCT00470509
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 subcutaneous injections on day 0 and 7
Trial: NCT01030666
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
Trial: NCT01030666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
Trial: NCT01030666
Drug: Ibuprofen 400 mg (if necessary)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
Trial: NCT00200343
Drug: Ursodeoxycholic acid 150mg / day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, 150mg/ day, three times a day at meals
Trial: NCT00200343
Drug: Ursodeoxycholic acid 600mg / day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, 600mg/ day, three times a day at meals
Trial: NCT00200343
Drug: Ursodeoxycholic acid 900mg / day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, 900mg/ day, three times a day at meals
Trial: NCT01785862
Drug: Ibuprofen 25 mg
RxNorm normalized name: diphenhydramine-ibuprofen 25 mg-200 mg oral capsule
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lozenge, Oromucosal administration
Trial: NCT01785862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenge matching V0498 lozenge, Oromucosal administration
Trial: NCT00869726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous, once every six months for 18 months
Trial: NCT00558831
Drug: Moisturizing Lotion
RxNorm normalized name: MOISTURIZING LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04529356
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
Trial: NCT00645450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly doses of placebo (inactive pill) following recollection of traumatic memory
Trial: NCT02654717
Drug: DFD-07 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02654717
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00529607
Drug: contrast echocardiography
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: directly after PCI, at 24 h after PCI, before discharge and at 6 months
Trial: NCT03658876
Drug: Iron Sucrose Solution for Injection
RxNorm normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg iron sucrose given on 5 successive haemodialysis sessions
Trial: NCT00680641
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg of Simvastatin once daily
Trial: NCT00680641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg of placebo once daily
Trial: NCT03007004
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with saline (0.2 ml). In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of saline (0.1 ml). A total of 1.0 ml of saline was injected into one hand. Injections were performed using a 30-gauge needle.
Trial: NCT02711917
Drug: MAC 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 MAC Sevoflurane
Trial: NCT02711917
Drug: MAC 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 MAC Sevoflurane
Trial: NCT02711917
Drug: MAC 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 MAC Sevoflurane
Trial: NCT04215965
Drug: Biphozyl (dialysate and replacement)
RxNorm normalized name: piperazine, 1-(4'-methoxy(1,1'-biphenyl)-2-yl)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacement solution with phosphate and without calcium in CRRT with citratre-based antigoagulation
Trial: NCT04215965
Drug: Prismocal B22 (dialysate) + phoxilium (replacement)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution with phosphate and calcium in CRRT with citratre-based antigoagulation
Trial: NCT02889367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.
Trial: NCT04679415
Drug: hzVSF-v13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7
Trial: NCT03137069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered orally, as per the dosing schedules described above.
Trial: NCT00003652
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03786783
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03786783
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01460511
Drug: Placebo-HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID